PE  Delos Capital

http://deloscap.com/





     Office Locations:

120 5th Ave.
3rd Floor
New York, NY 10011
Phone: 212-257-4450

 

Stages:

  • Middle Market


 

Industries:

  • Consumer Products & Services
  • Financial Services
  • Manufacturing & Industrial

  •  

    Description:

    Delos Capital is a lower-middle market private equity investment firm based in New York City. The Fund was formed in 2013 to invest in complex processes through Control Buyouts, Strategic Partnerships and Distressed Buyouts in companies with EBITDA of $5 - $30 million.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or New York Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Laura Lee
    Maria Orsini Messer Partner
    Matt Constantino Partner
    Mike Rakiter Partner
    Sanjay Sanghoee COO & CFO

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      11/13/2024


      TRexBio


      CA


      $84,000,000


      Series B


      10/23/2024


      Alpha-9 Oncology


      MA


      $175,000,000


      Series C


      07/16/2024


      Cardurion Pharmaceuticals


      MA


      $260,000,000


      Series B


      06/25/2024


      Exsilio Therapeutics


      NY


      $82,000,000


      Series A


     

    Portfolio companies include:


      Alpha-9 Oncology
        web link


      Antios Therapeutics
        web link


      BAROnova
        web link


      Cardurion Pharmaceuticals
        web link


      Curamir Therapeutics


      ECM


      Ensoma
        web link


      Exela


      Exsilio Therapeutics
        web link


      FCA


      Global Restoration


      HOP Energy


      ICP


      Instylla


      Intrinsic Therapeutics
        web link


      Mechanair


      OncoMyx
        web link


      OncoMyx Therapeutics
        web link


      Rgenta Therapeutics
        web link


      Sage Metals


      TRexBio
        web link


      United Flea Markets


      US Firness


     

    Recent News: